AITB - AIT Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.16
-0.04 (-0.77%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.20
Open5.20
Bid0.00 x 3200
Ask0.00 x 1300
Day's Range4.90 - 5.54
52 Week Range3.11 - 6.25
Volume21,831
Avg. Volume27,362
Market Cap52.585M
Beta (3Y Monthly)-0.43
PE Ratio (TTM)5.00
EPS (TTM)1.03
Earnings DateAug 12, 2019 - Aug 16, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.67
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    AIT Therapeutics Reports Financial Results for Fiscal Fourth Quarter and Year-End 2019 Results

    Announces name change to Beyond Air™ Completed uplisting to the NASDAQ and $7.96 million PIPE financing Anticipate PMA submission in the third quarter of calendar 2019.

  • GlobeNewswire10 days ago

    AIT Therapeutics Schedules Fiscal Year 2019 Financial Results Conference Call and Webcast

    GARDEN CITY, N.Y. and REHOVOT, Israel, June 17, 2019 -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on.

  • GlobeNewswire23 days ago

    AIT Therapeutics Announces $8 Million PIPE Financing

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that it has successfully executed funding agreements to raise $8 million through a private investment in public equity (PIPE) financing.

  • GlobeNewswire24 days ago

    AIT Therapeutics to Participate at Jefferies 2019 Global Healthcare Conference

    AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The AIT NO Delivery System can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time and has the ability to either titrate dose on demand or maintain a constant dose.  The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for lower respiratory tract infections that are not effectively addressed with current standards of care.

  • GlobeNewswire29 days ago

    AIT Therapeutics Announces Study Published in Journal of Cystic Fibrosis

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced the study, authored by Professor Lea Bentur, Director, Pediatric Pulmonary Institute, Rambam Medical Center, Haifa Israel, entitled, “Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection,” was published in the Journal of Cystic Fibrosis.

  • GlobeNewswirelast month

    AIT Therapeutics Presents On-Demand Nitric Oxide Study and Poster at the International Society for Aerosols in Medicine 2019 Congress in Montreux, Switzerland

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today presented data from its study: “On-Demand Nitric Oxide for Ventilator-Based Nitric Oxide Inhalation: A Risk-Reduction Perspective.” The study was presented as part of a session on pulmonary hypertension at the International Society for Aerosols in Medicine (ISAM) 2019 Congress in Montreux, Switzerland. “This study clearly shows the safety benefits of on-demand NO and we believe our ventilator-compatible Nitric Oxide Generator and Delivery System is the way of the future,” said Steve Lisi, Chairman and CEO.

  • GlobeNewswirelast month

    AIT Therapeutics Participating at the Oppenheimer MedTech Day on May 29

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that Steven Lisi, CEO, will participate in the Oppenheimer MedTech Day being held at the Hilton Union Square hotel in San Francisco on May 29, 2019. AIT Therapeutics Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases.

  • GlobeNewswirelast month

    AIT Therapeutics Presents Data at the 2019 American Thoracic Society Conference in Dallas, TX

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced it presented data from its study, entitled: “Synergistic Effect of Nitric Oxide with Antibiotics Against Mycobacterium Abscessus in Vitro” at the 2019 American Thoracic Society (ATS) Conference being held on May 17-22, 2019 in Dallas, TX.

  • GlobeNewswirelast month

    AIT Therapeutics Announces Oral and Poster Presentations at the International Society for Aerosols in Medicine 2019 Congress in Montreux, Switzerland

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, today announced an oral presentation to be given by Mark Rimkus, Vice President of Clinical Affairs, as part of a session on pulmonary hypertension on May 28 at the International Society for Aerosols in Medicine (ISAM) 2019 Congress being held on May 25-29, 2019 in Montreux, Switzerland.

  • GlobeNewswire2 months ago

    AIT Therapeutics to Present Data at the 2019 American Thoracic Society Conference in Dallas, TX

    GARDEN CITY, N.Y. and REHOVOT, Israel, May 08, 2019 -- AIT Therapeutics, Inc. (NASDAQ: AITB), a clinical-stage medical device and biopharmaceutical company focused on.

  • GlobeNewswire2 months ago

    AIT Therapeutics Announces Uplisting to the Nasdaq Capital Market

    “I would like to thank the Nasdaq team for allowing us to trade on their prestigious, globally recognized and trusted exchange,” said Steven Lisi, Chairman and Chief Executive Officer of AIT Therapeutics.

  • GlobeNewswire2 months ago

    AIT Therapeutics to Demonstrate NO Generator and Delivery System at Pediatric Academic Societies Meeting in Baltimore, MD on April 27-30

    AIT Therapeutics, Inc. (AITB), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions including serious lung infections and pulmonary hypertension, today announced that the Company will be exhibiting at the Pediatric Academic Societies (PAS) Annual meeting being held in Baltimore, MD on April 27-30, 2019. AIT will be exhibiting and demonstrating its NO Generator and Delivery System at booth # 951.

  • Recro Pharma Falls as FDA Denies Approval to Pain Candidate
    Zacks3 months ago

    Recro Pharma Falls as FDA Denies Approval to Pain Candidate

    FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.

  • Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan
    Zacks3 months ago

    Aerie (AERI) Starts Phase II Study on Eye Candidate in Japan

    Aerie (AERI) begins dosing in a phase II study on netarsudil ophthalmic solution in Japan for curbing high intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Shares Up.

  • Dermira (DERM) Catches Eye: Stock Jumps 12%
    Zacks3 months ago

    Dermira (DERM) Catches Eye: Stock Jumps 12%

    Dermira (DERM) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

  • ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session
    Zacks3 months ago

    ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session

    ChemoCentryx (CCXI) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

  • Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict
    Zacks3 months ago

    Karyopharm Stock Up Even as FDA Delays Selinexor NDA Verdict

    Karyopharm's (KPTI) stock rises despite the FDA's decision to delay the verdict on the NDA filing of selinexor, which is developed for treating patients with relapsed-refractory multiple myeloma.

  • Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down
    Zacks3 months ago

    Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down

    Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.

  • OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference
    PR Newswire3 months ago

    OTC Markets Group Announces Gold Sponsorship of 31st Annual ROTH Conference

    OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ --  OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...

  • GlobeNewswire3 months ago

    AIT Therapeutics to Participate at Two Investor Conferences in March

    GARDEN CITY, N.Y., and REHOVOT, Israel, March 13, 2019 -- AIT Therapeutics, Inc. (OTCQB: AITB), a clinical-stage medical device and biopharmaceutical company focused on.

  • Top Ranked Momentum Stocks to Buy for March 6th
    Zacks4 months ago

    Top Ranked Momentum Stocks to Buy for March 6th

    Top Ranked Momentum Stocks to Buy for March 6th

  • Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher
    Zacks4 months ago

    Amneal Pharmaceuticals (AMRX) Surges: Stock Moves 8.6% Higher

    Amneal Pharmaceuticals (AMRX) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

  • Zacks.com featured highlights include: Meet, Verint, First BanCorp, Sotherly and AIT
    Zacks4 months ago

    Zacks.com featured highlights include: Meet, Verint, First BanCorp, Sotherly and AIT

    Zacks.com featured highlights include: Meet, Verint, First BanCorp, Sotherly and AIT

  • 5 Stocks With Recent Price Strength to Strengthen Portfolio
    Zacks4 months ago

    5 Stocks With Recent Price Strength to Strengthen Portfolio

    Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

  • GlobeNewswire4 months ago

    AIT Therapeutics Reports Financial Results for Fiscal Third Quarter 2019

    Announced transformational partnership agreement with Circassia Pharmaceuticals  PMA filing for treatment of PPHN on track for second quarter calendar 2019  Completed.